ARCHIMED Acquires Stragen Pharma

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

September 25, 2025

Biotechnology

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO

December 16, 2021

Healthcare Services

Transatlantic healthcare private equity firm ARCHIMED, via its MED Platform I fund and in partnership with CAPZA Expansion and Siparex, has acquired a majority stake in Lyon-based CARSO, a leader in purity and analytical testing for pharma, healthcare, environmental and food sectors. The deal (debt provided by Tikehau Capital and several banks) will support CARSO's internationalization and service-range expansion as the group aims to more than double current annual revenues (above €200 million).

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.